Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806604 | 0.78 | PLAU (0.55) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL28205208 | 0.78 | SLC9A1 (0.47) | ALDH1A1SLC9A1MAPTGPR3CA2 | |
| SCHEMBL146453 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL31304802 | 0.77 | SLC9A1 (0.46) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL29208180 | 0.77 | SLC9A1 (0.46) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL21444811 | 0.75 | ALDH1A1 (0.50) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL12330261 | 0.75 | PLAU (0.51) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL17866234 | 0.75 | CA2 (0.53) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL147141 | 0.75 | ALDH1A1 (0.50) | ALDH1A1SLC9A1MAPTPLAUGPR3 | |
| SCHEMBL5646614 | 0.75 | SLC9A1 (0.45) | ALDH1A1SLC9A1MAPTGPR3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | disclosed |
| EP-1069106-B1 | Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity | GRUENENTHAL GMBH (DE) | 2004-01-28 | — | — | EP | disclosed |
| EP-0799819-B1 | 1-Dimethylaminomethyl 2-phenyl cycloalk-2-ene derivatives with analgesic activity | GRUENENTHAL GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1069106-A2 | Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity | Grünenthal GmbH (DE) | 2001-01-17 | — | — | EP | disclosed |
| EP-0983994-A2 | Pharmaceutically-active dimethyl-(3-aryl-but-3-enyl)-amine compounds | Grünenthal GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| EP-0799819-A1 | Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity | Grünenthal GmbH (DE) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | ALDH1A1 4417/4885SLC9A1 2064/4885MAPT 4627/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | ALDH1A1 4417/4885SLC9A1 2064/4885MAPT 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.